central-nervous-system
(3)
NeuShen Therapeutics
NeuShen Therapeutics is a clinical-stage biotech developing novel small-molecule and gene-therapy treatments for central nervous system disorders such as schizophrenia, depression and epilepsy. Founded in 2021 by Joan Huaqiong Shen, MD, PhD, and headquartered in Shanghai with an R&D center in the Boston area, the company runs a pipeline led by NS-136, a selective M4 receptor positive allosteric modulator for schizophrenia, and NS-041, a highly selective KCNQ2/3 activator for epilepsy and depression.
Atalanta Therapeutics
Atalanta Therapeutics is a Boston-based biotechnology company pioneering RNA interference (RNAi) therapies for diseases of the brain and spinal cord. Its proprietary divalent small interfering RNA (di-siRNA) platform is engineered to silence disease-causing genes durably and broadly across the central nervous system - long the hardest place in the body to reach with RNAi. Founded out of the RNA Therapeutics Institute at UMass Chan Medical School by leaders in the RNAi field, including Nobel laureate Craig Mello, the company is advancing wholly-owned programs in KCNT1-related epilepsy and Huntington's disease toward the clinic, alongside collaborations with Biogen and Genentech.
Ilise Lombardo
Ilise Lombardo is the CEO of Noema Pharma, a Basel-based clinical-stage biotech advancing treatments for central nervous system disorders. A Yale-trained psychiatrist with a Cambridge M.Phil and a Brown degree, she spent two decades in clinical practice and academia before co-founding Arvelle Therapeutics, which sold to Angelini Pharma for roughly $1 billion in 2021. She now steers Noema's pipeline of Phase 2 programs targeting Tourette syndrome, trigeminal neuralgia, tuberous sclerosis seizures and menopause-related CNS symptoms.